IL270285B2 - Diagnostic advanced glycation end-product antibodies - Google Patents

Diagnostic advanced glycation end-product antibodies

Info

Publication number
IL270285B2
IL270285B2 IL270285A IL27028519A IL270285B2 IL 270285 B2 IL270285 B2 IL 270285B2 IL 270285 A IL270285 A IL 270285A IL 27028519 A IL27028519 A IL 27028519A IL 270285 B2 IL270285 B2 IL 270285B2
Authority
IL
Israel
Prior art keywords
age
cells
sample
patient
disease
Prior art date
Application number
IL270285A
Other languages
English (en)
Hebrew (he)
Other versions
IL270285B1 (en
IL270285A (en
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of IL270285A publication Critical patent/IL270285A/en
Publication of IL270285B1 publication Critical patent/IL270285B1/en
Publication of IL270285B2 publication Critical patent/IL270285B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL270285A 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies IL270285B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501424P 2017-05-04 2017-05-04
US201762610003P 2017-12-22 2017-12-22
PCT/US2018/030931 WO2018204679A1 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Publications (3)

Publication Number Publication Date
IL270285A IL270285A (en) 2019-12-31
IL270285B1 IL270285B1 (en) 2025-02-01
IL270285B2 true IL270285B2 (en) 2025-06-01

Family

ID=62223287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270285A IL270285B2 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Country Status (9)

Country Link
US (1) US20200150131A1 (enExample)
EP (1) EP3619540A1 (enExample)
JP (2) JP2020521117A (enExample)
KR (2) KR20200003067A (enExample)
CN (1) CN110832327A (enExample)
AU (1) AU2018261622A1 (enExample)
CA (1) CA3062082A1 (enExample)
IL (1) IL270285B2 (enExample)
WO (1) WO2018204679A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913047A2 (pt) 2008-05-23 2013-03-05 Siwa Corp anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
MA40459A (fr) 2014-09-19 2016-03-24 Siwa Corp Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US20220175916A1 (en) * 2018-07-23 2022-06-09 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
EP4069723A4 (en) * 2019-12-02 2024-05-15 Viome Life Sciences, Inc. Detection and elimination of aberrant cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
IL297799A (en) 2020-05-01 2022-12-01 Siwa Corp Methods for treating infections
US20240000930A1 (en) 2020-12-09 2024-01-04 Siwa Corporation Methods and compositions for treating kidney diseases
US20240329058A1 (en) * 2021-04-09 2024-10-03 Gachon University Of Industry-Academic Cooperation Foundation Biomarker for neurodegenerative diseases comprising glycotoxin, specific protein bound to glycotoxin, or glycotoxin-specific protein complex
EP4388016A1 (en) 2021-08-20 2024-06-26 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用
CN118562721A (zh) * 2024-06-27 2024-08-30 广州市华代生物科技有限公司 一种基于全皮模型的糖化衰老模型及抗糖效果测试评价方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
JP4012722B2 (ja) * 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
BRPI0913047A2 (pt) 2008-05-23 2013-03-05 Siwa Corp anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula
JP5808801B2 (ja) * 2010-06-18 2015-11-10 ディアフノプティクス ホールディング ベー．フェー． 皮膚組織の自己蛍光値を求めるための方法および装置
RU2716256C2 (ru) * 2014-01-28 2020-03-11 Бак Инститьют Фо Ресеч Он Эйджинг Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением
WO2016040752A1 (en) * 2014-09-12 2016-03-17 The Procter & Gamble Company Anti-aging skin care compositions and regimens
US10358502B2 (en) * 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2018261622A1 (en) 2019-12-12
EP3619540A1 (en) 2020-03-11
JP2020521117A (ja) 2020-07-16
US20200150131A1 (en) 2020-05-14
IL270285B1 (en) 2025-02-01
KR20200003067A (ko) 2020-01-08
CN110832327A (zh) 2020-02-21
WO2018204679A1 (en) 2018-11-08
IL270285A (en) 2019-12-31
JP2023098996A (ja) 2023-07-11
KR20240006702A (ko) 2024-01-15
RU2019139256A (ru) 2021-06-07
CA3062082A1 (en) 2018-11-08
RU2019139256A3 (enExample) 2022-01-18

Similar Documents

Publication Publication Date Title
IL270285B2 (en) Diagnostic advanced glycation end-product antibodies
US11833202B2 (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US20210253739A1 (en) Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells
US10858449B1 (en) Methods and compositions for treating osteoarthritis
IL281714B2 (en) Methods for increasing efficacy of folr1 cancer therapy
US20210011031A1 (en) Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same
JP6890581B2 (ja) Ｃｄ３７の検出のための抗体およびアッセイ
IL292176A (en) Humanized antibody and method for using the same
Yu et al. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety
Del Giudice et al. Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?
JP2023553247A (ja) がん診断のための組成物および方法
RU2788905C2 (ru) Диагностические антитела к конечным продуктам глубокого гликирования
Li et al. Acid sphingomyelinase-ceramide induced vascular injury determines colorectal cancer stem cell fate
JP7762937B2 (ja) 膵臓がんの診断補助方法及び膵臓がん治療用医薬組成物
US12459998B2 (en) Alpha-synuclein binding antibodies, or antigen binding portions thereof
HK40081546A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40029952B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40029952A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
WO2023049830A1 (en) Detecting and treating conditions associated with neuronal senescence
HK1256931B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
Lu Developing blood-based biomarkers of disease progression in Amyotrophic Lateral Sclerosis